open-label BE trials maintain blindness [Study Per­for­mance]

posted by kimhuang – China, 2023-10-14 11:19 (635 d 04:58 ago) – Posting: # 23752
Views: 5,961

How do open-label BE trials maintain blindness until the database is locked?
Holding a data review meeting before DBL to discuss whether PK parameters (such as Pre-dose concentration, Abnormal PK concentration profiles, λz estimation, %AUCextrap etc.) are included in the analysis set (without treatment assigment) will have risk of potential unblinding?


Edit: Category changed; see also this post #1[Helmut]

Complete thread:

UA Flag
Activity
 Admin contact
23,428 posts in 4,929 threads, 1,682 registered users;
63 visitors (0 registered, 63 guests [including 9 identified bots]).
Forum time: 16:18 CEST (Europe/Vienna)

To know that we know what we know,
and to know that we do not know what we do not know,
that is true knowledge.    Nicolaus Copernicus

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5